According to AllTheResearch’s analysts, increasing prevalence of cancer and its mutated forms, side effects of radiation therapy, need for targeted therapy, and high immunospecificity through monoclonal antibodies are the key drivers for the Radioimmunotherapy market ecosystem. The Radioimmunotherapy market ecosystem is still in its nascent stage, as there is only one approved product. However, the emerging clinical pipeline of radioimmunotherapy looks promising, and it will create growth opportunities for the radioimmunotherapy market ecosystem.
Get Sampl Copy of Report @ https://www.alltheresearch.com/sample-request/391
Various advanced stages of cancer and patients having relapsed and refractory cases are resistant to conventional treatment, such as chemotherapy and radiation therapy. Therefore, oncologists are continuously looking at advanced treatment options to treat such treatment-resistant cancer. This is creating demand for advanced treatment options such as radioimmunotherapy.
The key players operating in the Radioimmunotherapy market ecosystem are Bayer AG, Actinium Pharmaceuticals, Acrotech Ltd, Nordic Nanovector, and Orano Med, amongst others. Mergers & acquisitions and strategic partnerships with key players across the value chain are some of the key strategies adopted by companies to sustain in the market.
The main focus of companies in this market is research & development of new radioimmunotherapy agents and expansion of their production capacities. For instance, the announcement of the new US site for Betalutin® by Nordic Nanovector for PARADIGME Trials.
Companies have also been focusing on mergers & acquisitions strategy for entering the radioimmunotherapy market ecosystem. For instance, Acrotech Biopharma acquired Spectrum Pharmaceutical’s product portfolio for strengthening its oncology product portfolio. Similarly, in order to enter the radioimmunotherapy market, BioNTech has acquired MabVax in 2019.
Figure 1: Segmentation of Radioimmunotherapy Market Ecosystem
| Drug Type | Procedure Type | Radioisotope | Indication | End-user |
| Apamistamab | Alpha Emission | Yttrium-90 | Leukemia | Hospitals |
| Epratuzumab | Beta Emission | Iodine-131 | Lymphoma | Physician offices and Physician Group Practices |
| Ibritumomab |
| Thorium-227 | Breast cancer | Drug R&D |
| Streptavidin Fusion Protein |
| Bismuth-212 (Lead212) | Lung cancer |
|
| Lilotomab |
| Actinium-225 | Prostate cancer |
|
| Omburtamab |
| Lutetium-177 | Others |
|
| Others |
| Others |
|
|
Based on the procedure type, the beta emitting radioimmunotherapy market accounted for a share of 95.0% in 2019. The demand for alpha emitting radionuclides for radioimmunotherapy is also anticipated to remain high in the coming years, with a market share of 4.3% in 2027. Alpha emitting radionuclides are highly cytotoxic and provide high linear energy transfer (LET) in a short path length to the cancer cells. In radioimmunotherapy, the commonly used alpha emitters are Actinium-225, Astatine-211, Bismuth- 212, Bismuth-213, and Thorium-227. These alpha emitting radionuclides are coupled to antibodies with the help of a chelating agent.
Several clinical trials are currently being conducted for studying the clinical efficacy of various beta emitters such as Lu-177, Iodine-131, and Yttrium-90. Hence, beta emitters will be a lucrative segment for investment in the coming years.
Antibody fragments are currently under research to be used as a biologic molecule in radioimmunotherapy. Antibody fragments are smaller in size and hence, they can efficiently cross the cell barrier in case of solid tumors. This makes antibody fragments an attractive investment proposition for radioimmunotherapy manufacturers.
Very few markets have the interconnectivity with other markets like radioimmunotherapy. Our Interconnectivity module focuses on the key nodes of heterogeneous markets in detail. Radiopharmaceuticals, Monoclonal Antibodies, Oncology, and Nuclear Medicine markets are some of our key researched markets.
Log in / Register